Latest News

Neuren has announced that its partner Acadia has submitted a Marketing Authorisation Application to the EMAfor DAYBUE (trofinetide) for the treatment of Rett syndrome.

Vaxxas CEO David Hoey said, “We're honoured to have our world-leading microarray patch technology chosen to be part of this important BARDA-led public health initiative to accelerate new vaccine technologies."

Global Contract Development and Manufacturing Organisations BioCina and NovaCina have announced a strategic merger to create a new biopharmaceutical and small molecule contract manufacturing brand.

Monash University says scientists have identified an immune system trigger for severe bee venom allergy. This allergy lands twice as many Australians in hospital emergency departments yearly as snake or spider bites.

Race Oncology (ASX:RAC) has announced the appointment of experienced biotechnology executive Dr Megan Baldwin to its board as an independent non-executive director.

The scientists behind Australia’s first locally developed mRNA COVID-19 vaccine candidate have published a preclinical study demonstrating the vaccine's potential to overcome the issue of ‘immune imprinting.’

Australian biotechnology company Cartherics, which is developing immune cell therapies for cancer and other diseases, has been awarded a US$300,000 G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.

“If you have ovarian cancer, ask your oncologist to consider a test that will help determine whether your cancer is one of just under 50 per cent that might be responsive to new treatment options such as PARP inhibitors," says cancer researcher Professor Anna deFazio.

Australasian Biotechnology is AusBiotech’s official biannual journal, published in September and April. Written by the sector, for the sector highlighting topics such as technology development, manufacturing excellence, sustainability, and strategies to strengthen Australia’s end-to-end life sciences value chain.

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II in humans.

AusBiotech has formalised a new partnership with BioNSW, a rapidly growing not-for-profit organisation dedicated to harnessing the full potential of the New South Wales Life Sciences sector.